CTI Clinical Trial and Consulting Services Opens Geel, Belgium Office

FOR IMMEDIATE RELEASE [Cincinnati, OH ~ November 18, 2014] CTI Clinical Trial and Consulting Services (CTI), a multi-national, privately held, full-service contract research organization announces that is has opened an office in Geel, Belgium. The office is opened through the wholly-owned subsidiary, CTI Clinical Trial and Consulting Services Belgium SPRL. This is the company’s sixth new office opened this year, with additional new offices expected to be announced in the next several months. “We have had CTI employees in Belgium for the past several years working on behalf of our pharmaceutical and biotechnology clients, but it felt like it was time to formalize an office in the country,” according to Patrick Earley, Vice President, International. “Belgium is desirable for clinical trials due to innovative regulatory agencies, as well as excellent academic centers and researchers, leading to rapid study start up timelines and high enrollment at sites.” CTI has been working for over fifteen years in the drug development industry in North America, Europe, South America, and Pac-Asia, specializing in clinical research programs involving critically ill patient populations, and has more than 20 offices worldwide to serve more than 80 pharmaceutical, biotechnology, and medical device clients. Media Contact Allison Schroeder 513.598.9290 [email protected] About CTI Clinical Trial and Consulting Services CTI Clinical Trial and Consulting Services is an innovative, international drug and device development organization that delivers a full spectrum of clinical trial and consulting services from bench to commercialization with a focus on immunology and a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. CTI’s focused therapeutic approach provides pharmaceutical, biotechnology and startup firms with clinical and disease area expertise from a unique mix of academic, medical and industry specialists; rich intellectual capital in transplantation, immunology, infectious diseases, hematology, cardiology, nephrology, hepatology, regenerative medicine and rare diseases; flexible study designs that accelerate development programs and deliver high approval ratings that are among the best in the industry; and exceptional global project management and gold standard safety and data management systems that strengthen their program’s success potential. Established in 1999 and headquartered in Cincinnati, OH; CTI has offices in North America, Europe and South America.

Suggested Articles

Loh joins the computational chemistry specialist after a two-year stint at Kymera Therapeutics.

The $3 billion funding boost includes an additional $350 million for targeted Alzheimer’s research.

Less than two years after taking the reins from founding chief Rusty Williams, Five Prime Therapeutics CEO Aron Knickerbocker is exiting the company.